- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 401/02 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
Patent holdings for IPC class C07D 401/02
Total number of patents in this class: 629
10-year publication summary
36
|
40
|
48
|
35
|
34
|
32
|
38
|
48
|
30
|
22
|
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
Owner |
All patents
|
This class
|
---|---|---|
Merck Sharp & Dohme Corp. | 2194 |
15 |
Boehringer Ingelheim International GmbH | 4650 |
13 |
AstraZeneca AB | 2909 |
11 |
Medshine Discovery Inc. | 600 |
11 |
Merck Sharp & Dohme LLC | 3748 |
10 |
Bristol-myers Squibb Company | 4898 |
9 |
Takeda Pharmaceutical Company Limited | 2713 |
8 |
Janssen Pharmaceutica N.V. | 3392 |
7 |
Abbvie Inc. | 1800 |
7 |
Vertex Pharmaceuticals Incorporated | 1597 |
7 |
RespiVert Ltd. | 78 |
7 |
Sunshine Lake Pharma Co., Ltd. | 599 |
7 |
Epizyme, Inc. | 370 |
6 |
Alcon, Inc. | 5425 |
5 |
Angion Biomedica Corp. | 61 |
5 |
BeiGene, Ltd. | 367 |
5 |
MyoKardia, Inc. | 107 |
5 |
Nanoquantum Sciences, Inc. | 6 |
5 |
Insilico Medicine IP Limited | 126 |
5 |
Xizang Haisco Pharmaceutical Co., Ltd. | 96 |
5 |
Other owners | 476 |